Epratuzumab

Epratuzumab is a humanized monoclonal antibody. Potential uses may be found in oncology and in treatment of inflammatory autoimmune disorders, such as lupus (SLE). The manufacturers in August 2009 announced success in early trials against SLE.

Mechanism
Epratuzumab binds to the glycoprotein CD22 of mature and malignant B-cells.